The Global Non-narcotic analgesics market is estimated to grow at a significant CAGR during the forecast period. Non-opioid analgesics are drugs used to relieve pain; however, because most opioid drugs are misused at some point by patients or other people for non-medical purposes, the use of opioid drugs is suggested to be lowered by many healthcare professionals. Non-narcotic analgesics are pain and inflammation-controlling drugs. A non-narcotic drug is one that has antipyretic, analgesic, and anti-inflammatory properties. Non-narcotic analgesics have no effect on opioid receptors. Some of these drugs can be used during surgery to decrease post-operative pain, and reduce the need for narcotics.
A full report of Non-narcotic analgesics Market is available at: https://www.omrglobal.com/industry-reports/non-narcotic-analgesics-market
The rising incidence of chronic diseases such as cancer, where different therapies such as chemotherapy are to responsible for pain, is expected to fuel the expansion of the non-opioid analgesics market. The rising number of surgeries is expected to increase the prevalence of post-operative pain, driving the expansion of the non-opioid analgesics market. The growing number of persons suffering neuropathic pain is expected to fuel the expansion of the non-opioid analgesics industry. According to NCBI, Non-narcotic analgesics are effectiveness for a wide spectrum of pain and inflammatory disorders, non-opioid analgesics are among the most commonly used medicines. Over 172 million prescriptions for cyclooxygenase (COX) inhibitors (both selective and non-selective) were issued in the United States alone.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/non-narcotic-analgesics-market
In June 2019, Ironwood Pharmaceuticals and Allergan started treating patients in a Phase II Clinical Trial of MD-7246 in individuals with irritable bowel syndrome and diarrhoea (IBS-D). The drug is being tested as an oral, intestinal, non-opioid pain reliever for individuals with abdominal pain caused by gastrointestinal disorders.
In June 2018, Sandoz Canada announced a collaboration with Tilray, a Health Canada-licensed medical cannabis producer, to become the first Canadian pharmaceutical firm to enter the medical cannabis sector.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment covered
o By Type
o By Application
- Region covered
o North America
o Europe
o Asia-Pacific
o Rest of the world
- Competitive Landscape – Akron, Inc., BioDelivery Sciences International, Inc., Endo Pharmaceuticals., GlaxoSmithKline PLC., Novartis AG., Pfizer., Sanofi S.A, and Teva Pharmaceuticals., among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominates the market in base year?
- Which segment and region will project fastest growth in the market?
- How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Market Segmentation
By Type
- Non Steroid Anti – inflammatory Drug
- Steroid Anti – inflammatory Drug
By Application
- Hospital
- Medical Center
- Others
Company Profiles
- Akron, Inc.
- BioDelivery Sciences International, Inc.
- Endo Pharmaceuticals.
- GlaxoSmithKline PLC.
- Novartis AG.
- Pfizer
- Sanofi S.A
- Teva Pharmaceuticals
This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.
